 | • レポートコード：MRC2301D011 • 出版社/出版日：Transparency Market Research / 2022年11月24日 • レポート形態：英文、PDF、213ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の市場調査書では、世界の抗放射線薬市場について調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、化合物別（ヨウ化カリウム（KI）、プルシアンブルー、五酢酸ジエチレントリアミン（DTPA）、その他）分析、用途別（急性放射線症候群（ARS）、がん治療、放射線被曝、その他）分析、流通チャネル別（病院薬局、小売薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を整理しました。並びに、当書に掲載されている企業情報には、Amgen Inc.、Anbex Inc.、Arco Pharmaceuticals LLC、BTG International Inc.、Cellphire, Inc.、Chrysalis BioTherapeutics, Inc.、Darnitsa、Enzychem Lifesciences Corporation、Humanetics Corporation、Mission Pharmacal Company、Myelo Therapeutics GmbH、Partner Therapeutics、Pluri Inc.、Other Playersなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の抗放射線薬市場規模：化合物別 - ヨウ化カリウム（KI）の市場規模 - プルシアンブルーの市場規模 - 五酢酸ジエチレントリアミン（DTPA）の市場規模 - その他抗放射線薬の市場規模 ・世界の抗放射線薬市場規模：用途別 - 急性放射線症候群（ARS）における市場規模 - がん治療における市場規模 - 放射線被曝における市場規模 - その他用途における市場規模 ・世界の抗放射線薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - その他チャネルの市場規模 ・世界の抗放射線薬市場規模：地域別 - 北米の抗放射線薬市場規模 - ヨーロッパの抗放射線薬市場規模 - アジア太平洋の抗放射線薬市場規模 - 中南米の抗放射線薬市場規模 - 中東・アフリカの抗放射線薬市場規模 ・競争状況 |
Anti-Radiation Drugs Market – Scope of Report
TMR’s report on the global anti-radiation drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global anti-radiation drugs market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anti-radiation drugs market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the anti-radiation drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anti-radiation drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global anti-radiation drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anti-radiation drugs market.
The report delves into the competitive landscape of the global anti-radiation drugs market. Key players operating in the global anti-radiation drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global anti-radiation drugs market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market anti-radiation drugs.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anti-radiation Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anti-radiation Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Industry Events (Partnership, Investment, Merger & Acquisition, etc.)
5.3. Insights on Radiation Pills
5.4. Regulatory Scenario, by Key Region/ Country
5.5. COVID-19 Impact Analysis
6. Global Anti-radiation Drugs Market Analysis and Forecast, by Compound
6.1. Introduction & Definition
6.2. Market Value Forecast, by Compound, 2017–2031
6.2.1. Potassium Iodide (KI)
6.2.2. Prussian Blue
6.2.3. DTPA (Diethylenetriamine Pentaacetate)
6.2.4. Others
6.3. Market Attractiveness, by Compound
7. Global Anti-radiation Drugs Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Market Value Forecast, by Application, 2017–2031
7.2.1. Acute Radiation Syndrome (ARS)
7.2.2. Cancer Treatment
7.2.3. Radiation Exposure
7.2.4. Others
7.3. Market Attractiveness Analysis, by Application
8. Global Anti-radiation Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Market Value Forecast, by Distribution Channel, 2017–2031
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Others
8.3. Market Attractiveness Analysis, by Distribution Channel
9. Global Anti-radiation Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Anti-radiation Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Compound, 2017–2031
10.2.1. Potassium Iodide (KI)
10.2.2. Prussian Blue
10.2.3. DTPA (Diethylenetriamine Pentaacetate)
10.2.4. Others
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Acute Radiation Syndrome (ARS)
10.3.2. Cancer Treatment
10.3.3. Radiation Exposure
10.3.4. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Compound
10.6.2. By Application
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Anti-radiation Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Compound, 2017–2031
11.2.1. Potassium Iodide (KI)
11.2.2. Prussian Blue
11.2.3. DTPA (Diethylenetriamine Pentaacetate)
11.2.4. Others
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Acute Radiation Syndrome (ARS)
11.3.2. Cancer Treatment
11.3.3. Radiation Exposure
11.3.4. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Compound
11.6.2. By Application
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Anti-radiation Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Compound, 2017–2031
12.2.1. Potassium Iodide (KI)
12.2.2. Prussian Blue
12.2.3. DTPA (Diethylenetriamine Pentaacetate)
12.2.4. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Acute Radiation Syndrome (ARS)
12.3.2. Cancer Treatment
12.3.3. Radiation Exposure
12.3.4. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Compound
12.6.2. By Application
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Anti-radiation Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Compound, 2017–2031
13.2.1. Potassium Iodide (KI)
13.2.2. Prussian Blue
13.2.3. DTPA (Diethylenetriamine Pentaacetate)
13.2.4. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Acute Radiation Syndrome (ARS)
13.3.2. Cancer Treatment
13.3.3. Radiation Exposure
13.3.4. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Compound
13.6.2. By Application
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Anti-radiation Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Compound, 2017–2031
14.2.1. Potassium Iodide (KI)
14.2.2. Prussian Blue
14.2.3. DTPA (Diethylenetriamine Pentaacetate)
14.2.4. Others
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Acute Radiation Syndrome (ARS)
14.3.2. Cancer Treatment
14.3.3. Radiation Exposure
14.3.4. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Compound
14.6.2. By Application
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. Amgen Inc.
15.3.1.1. Company Overview
15.3.1.2. Compound Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Anbex Inc.
15.3.2.1. Company Overview
15.3.2.2. Compound Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Arco Pharmaceuticals LLC
15.3.3.1. Company Overview
15.3.3.2. Compound Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.4. BTG International Inc.
15.3.4.1. Company Overview
15.3.4.2. Compound Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Cellphire, Inc.
15.3.5.1. Company Overview
15.3.5.2. Compound Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Chrysalis BioTherapeutics, Inc.
15.3.6.1. Company Overview
15.3.6.2. Compound Portfolio
15.3.6.3. SWOT Analysis
15.3.7. Darnitsa
15.3.7.1. Company Overview
15.3.7.2. Compound Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Enzychem Lifesciences Corporation
15.3.8.1. Company Overview
15.3.8.2. Compound Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Humanetics Corporation
15.3.9.1. Company Overview
15.3.9.2. Compound Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Mission Pharmacal Company
15.3.10.1. Company Overview
15.3.10.2. Compound Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Myelo Therapeutics GmbH
15.3.11.1. Company Overview
15.3.11.2. Compound Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Partner Therapeutics
15.3.12.1. Company Overview
15.3.12.2. Compound Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Pluri Inc.
15.3.13.1. Company Overview
15.3.13.2. Compound Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. Other Players
15.3.14.1. Company Overview
15.3.14.2. Compound Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview